**SUPPLEMENTARY DATA**

**Supplementary table S1: clinical and demographic patient characteristics from SLE patients – serum cohort**

|  |  |  |
| --- | --- | --- |
|  | **HC (n=20)** | **SLE (n=30)** |
| Age, years, median (IQR) | 44 (35 – 50) | 43 (35 – 53) |
| Female | 90 | 93 |
| SELENA-SLEDAI, median (IQR) |  | 4 (2-6) |
| anti-dsDNA, EliA, IU/mL, median (IQR)  |  | 20 (3 – 66) |
| C3, g/L, median (IQR) |  | 0.84 (0.75 – 0.99) |
| C4, g/L, median (IQR) |  | 0.15 (0.12 – 0.21) |
| SLE duration, years, median (IQR) |  | 12 (8 – 21) |
| Lupus Nephritis (history of) |  | 50 |
| eGFR <90 ml/min |  | 30 |
| **Current drug use** |  |  |
| Prednisone |  | 57 |
| Prednisone dose, mg/day, median (IQR) |  | 7.5 (5 – 10) |
| Hydroxychloroquine |  | 53 |
| Azathioprine |  | 40 |
| Mycophenolate mofetil |  | 10 |

Table shows percentage of total unless otherwise stated. HC: healthy controls; SLENA:

**Supplementary table S2: Patient characteristics from SLE patients – biopsy cohort**

|  |  |
| --- | --- |
|  | **SLE n=38** |
| Biopsies | 38 |
| Number of patients | 34 |
| Female, % | 78 |
| Age, years, median (IQR) | 33 (23 – 51) |
| Creatinine, uMol/L prior to biopsy, median (IQR) | 27 (60 – 107) |
| Proteinuria, g/L, prior to biopsy, median (IQR) | 1.15 (0.52 – 2.8) |
| Renal SLEDAI, prior to biopsy, median (IQR) | 12 (8 – 16) |